SCHEMBL14029232

SCHEMBL14029232

CCN(CCC#N)C(=O)CN(C)S(=O)(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 2/20 0.52
MMP9 P14780 1/20 0.46
MMP13 P45452 1/20 0.46
MLYCD O95822 2/20 0.43
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA4 P22748 1/20 0.41
TSHR P16473 3/20 0.39
ALDH1A1 P00352 7/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
MAPT P10636 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1038147 0.83 HCRTR2 (0.78) HCRTR2TSHRALDH1A1KEAP1NFE2L2
SCHEMBL1035705 0.72 HCRTR2 (0.64) HCRTR2CA12CA1CA2CA4
SCHEMBL12169361 0.70 ALDH1A1 (0.47) HCRTR2CA12CA1CA2ALDH1A1
SCHEMBL1037049 0.70 HCRTR2 (0.87) HCRTR2TSHRALDH1A1KEAP1NFE2L2
SCHEMBL1039384 0.69 HCRTR2 (0.80) HCRTR2TSHRALDH1A1HSD17B10KMT2A
SCHEMBL1040589 0.69 HCRTR2 (0.61) HCRTR2ALDH1A1KEAP1NFE2L2
SCHEMBL12169354 0.69 ALDH1A1 (0.51) HCRTR2ALDH1A1KDM4EKMT2ALMNA
SCHEMBL1039013 0.68 HCRTR2 (1.00) HCRTR2TSHRALDH1A1KEAP1NFE2L2
SCHEMBL12169390 0.68 TDP1 (0.46) HCRTR2ALDH1A1KDM4EKMT2ALMNA
SCHEMBL1039429 0.68 HCRTR2 (0.80) HCRTR2ALDH1A1KMT2AKEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435815-B2 Sulfonylamino-acetic acid derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-10-14 US disclosed
US-7435815-B2 Sulfonylamino-acetic acid derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-10-14 US disclosed
US-20070244156-A1 SULFONYLAMINO-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2007-10-18 US disclosed
US-20070244156-A1 SULFONYLAMINO-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244156-A1 SULFONYLAMINO-ACETIC ACID DERIVATIVES HCRTR2, HCRTR1, GIPR HCRTR2 1/4885MMP9 4647/4885MMP13 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.